Skip to content
TrialScanner

NCT02562443

Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA

Phase 3TerminatedTRAWLead

Registry record

Lead sponsor
Traws Pharma, Inc.
Conditions
Myelodysplastic Syndrome; MDS; Refractory Anemia With Excess Blasts; RAEB
Primary completion
Jul 26, 2020Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT02562443 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT02562443: Controlled Study of Rigoserti... | TrialScanner